Fingolimod
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Relapsing-remitting Multiple Sclerosis
Conditions
Relapsing-remitting Multiple Sclerosis
Trial Timeline
Feb 1, 2011 → Jul 1, 2012
NCT ID
NCT01310166About Fingolimod
Fingolimod is a approved stage product being developed by Novartis for Relapsing-remitting Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01310166. Target conditions include Relapsing-remitting Multiple Sclerosis.
What happened to similar drugs?
6 of 20 similar drugs in Relapsing-remitting Multiple Sclerosis were approved
Approved (6) Terminated (6) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04480853 | Approved | Recruiting |
| NCT05141669 | Pre-clinical | Completed |
| NCT03257358 | Approved | Completed |
| NCT02720107 | Approved | Completed |
| NCT02232061 | Approved | Completed |
| NCT01621269 | Approved | Withdrawn |
| NCT01755871 | Approved | Terminated |
| NCT01578330 | Approved | Completed |
| NCT01705236 | Approved | Completed |
| NCT01497262 | Phase 3 | Completed |
| NCT01285479 | Pre-clinical | Completed |
| NCT01420055 | Approved | Completed |
| NCT01281657 | Pre-clinical | Completed |
| NCT01310166 | Approved | Completed |
| NCT01201356 | Phase 3 | Completed |
| NCT00670449 | Phase 2 | Completed |
Competing Products
20 competing products in Relapsing-remitting Multiple Sclerosis